Zurzuvae PPD denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Zurzuvae for Postpartum Depression as Experimental

Zurzuvae (zuranolone) received FDA approval for postpartum depression (PPD), making an "experimental" or "investigational" classification from Aetna directly rebuttal-able. This type of denial typically arises when Aetna's clinical policy bulletin has not yet been updated to reflect the FDA approval, when the policy lists specific population criteria and the patient's documentation does not clearly place her within that population, or when the claim was coded in a way that triggered an automated experimental flag.

Because PPD carries real risks to both the patient and infant, delay caused by an incorrect experimental denial is not a neutral harm. Federal law under ACA §2719 guarantees access to independent external review of these denials, and external reviewers apply an objective evidence-based standard — not the insurer's internal policy — to assess whether a treatment is truly experimental.

## Your Appeal Rights

• Internal appeal: File within the deadline on the denial letter. Under ERISA §503 (employer plans), you are entitled to a full-and-fair review and access to all clinical criteria and guidelines Aetna relied upon.
• External review (ACA §2719): After an adverse internal decision, independent external review is available. The standard window is up to four months from the final internal denial. Given the urgency of untreated PPD, request expedited external review simultaneously — reviewers must respond within 72 hours for urgent cases.
• Mental Health Parity (MHPAEA): Raise parity if Aetna applies the experimental label more readily to psychiatric medications than to physically analogous drugs at similar stages of adoption. Document the disparity in your appeal.
• State insurance department: For fully-insured state-regulated plans, your state insurance commissioner can receive complaints when an FDA-approved therapy is mislabeled as experimental.

## Documentation to Gather

1. FDA approval documentation — download the FDA label and approval letter from fda.gov and submit them as exhibit A. This is the foundational document for overturning an experimental denial. 2. Diagnosis confirmation — physician documentation of postpartum depression diagnosis with onset date relative to delivery and clinical severity assessment. 3. Prior treatment history — log of all prior antidepressant or other psychiatric treatments tried, with dates and documented outcomes. 4. Clinical severity and urgency — validated screening results, clinical notes on functional impairment, and any documentation of risk factors requiring timely treatment. 5. Prescriber letter — the treating physician should explicitly confirm FDA-approved status, state the specific FDA-approved indication being sought, and explain why Zurzuvae is the appropriate choice for this patient's clinical profile. 6. Applicable guideline reference — cite guidance from the relevant professional organization (e.g., American College of Obstetricians and Gynecologists, American Psychiatric Association) supporting Zurzuvae's role in PPD management.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin for Zurzuvae and the FDA-approved prescribing label. Address each criterion listed:

| Denial Basis / Policy Criterion | Response + Supporting Document | |---|---| | FDA approval status | FDA label + approval letter (attached) | | Confirmed PPD diagnosis | Physician note with delivery date, [date] | | Severity and clinical appropriateness | Screening results + prescriber note | | Prior treatment history | Medication log with dates | | Prescriber specialty and attestation | Treating physician credentials and letter |

Open the appeal letter with a clear statement of FDA approval and attach the label immediately. Reframing the insurer's classification from "experimental" to "coverage restriction" — and showing that the specific policy language does not support the experimental label for an FDA-approved therapy — is the strongest argument in external review.